Nasdaq · CIK 0001734750
MOVE Movano Inc.
Insider trading from SEC Form 4. Last filing Mar 19, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
7
with a Form 4 at this company
Signals
Open-market buys and sells at Movano Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Jeremy Cogan CFO sell | $597k 28,736 shares | -32% | - | |
| 26Weak | Jeremy Cogan CFO sell | $80k 10,097 shares | -40% | - |
Transactions
The last 65 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | Jeremy Cogan CFO | AGrant or award Common Stock | +37,000 | $0.00 | $0 | 97,504 | Mar 19, 2026 |
| Mar 18, 2026 | Emily Fairbairn director | AGrant or award Stock option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Mar 19, 2026 |
| Mar 19, 2026 | Emily Fairbairn director | AGrant or award Series B Preferred Stockderivative | +9 | $0.00 | $0 | 9 | Mar 19, 2026 |
| Mar 19, 2026 | Emily Fairbairn director | AGrant or award Series C Preferred Stockderivative | +2,064 | $0.00 | $0 | 2,064 | Mar 19, 2026 |
| Mar 16, 2026 | Emily Fairbairn director | MOption exercise Common Stock | +55,250 | $1.25 | $69k | 68,369 | Mar 17, 2026 |
| Mar 16, 2026 | Emily Fairbairn director | MOption exercise Stock Options (Right to Buy)derivative | -55,250 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Jan 26, 2026 | Jeremy Cogan CFO | MOption exercise Common Stock | +64,834 | $1.25 | $81k | 89,240 | Jan 28, 2026 |
| Jan 27, 2026 | Jeremy Cogan CFO | SOpen-market sale Common Stock | -3,288 | $19.11 | $63k | 85,952 | Jan 28, 2026 |
| Jan 27, 2026 | Jeremy Cogan CFO | SOpen-market sale Common Stock | -4,622 | $20.07 | $93k | 81,330 | Jan 28, 2026 |
| Jan 27, 2026 | Jeremy Cogan CFO | SOpen-market sale Common Stock | -13,179 | $20.63 | $272k | 68,151 | Jan 28, 2026 |
| Jan 27, 2026 | Jeremy Cogan CFO | SOpen-market sale Common Stock | -5,548 | $21.76 | $121k | 62,603 | Jan 28, 2026 |
| Jan 27, 2026 | Jeremy Cogan CFO | SOpen-market sale Common Stock | -2,099 | $23.37 | $49k | 60,504 | Jan 28, 2026 |
| Jan 26, 2026 | Jeremy Cogan CFO | MOption exercise Stock Options (Right to Buy)derivative | -64,834 | $0.00 | $0 | 0 | Jan 28, 2026 |
| Jan 9, 2026 | Ruben Caballero director | AGrant or award Common Stock | +2,980 | $0.00 | $0 | 3,515 | Jan 12, 2026 |
| Jan 9, 2026 | Brian Cullinan director | AGrant or award Common Stock | +4,768 | $0.00 | $0 | 6,642 | Jan 12, 2026 |
| Jan 5, 2026 | Jeremy Cogan CFO | MOption exercise Common Stock | +20,000 | $1.25 | $25k | 25,204 | Jan 12, 2026 |
| Jan 9, 2026 | Emily Fairbairn director | AGrant or award Common Stock | +4,470 | $0.00 | $0 | 7,160 | Jan 12, 2026 |
| Jan 9, 2026 | Brian Cullinan director | AGrant or award Common Stock | +2,980 | $0.00 | $0 | 9,622 | Jan 12, 2026 |
| Jan 5, 2026 | Jeremy Cogan CFO | SOpen-market sale Common Stock | -1,879 | $8.35 | $16k | 23,325 | Jan 12, 2026 |
| Jan 9, 2026 | Emily Fairbairn director | AGrant or award Common Stock | +5,959 | $0.00 | $0 | 13,119 | Jan 12, 2026 |
| Jan 9, 2026 | Ruben Caballero director | AGrant or award Common Stock | +2,980 | $0.00 | $0 | 6,495 | Jan 12, 2026 |
| Jan 6, 2026 | Jeremy Cogan CFO | SOpen-market sale Common Stock | -3,859 | $8.03 | $31k | 19,466 | Jan 12, 2026 |
| Jan 6, 2026 | Jeremy Cogan CFO | SOpen-market sale Common Stock | -4,359 | $7.57 | $33k | 15,107 | Jan 12, 2026 |
| Jan 9, 2026 | Jeremy Cogan CFO | AGrant or award Common Stock | +9,299 | $0.00 | $0 | 24,406 | Jan 12, 2026 |
| Jan 5, 2026 | Jeremy Cogan CFO | MOption exercise Stock Options (Right to Buy)derivative | -20,000 | $0.00 | $0 | 64,834 | Jan 12, 2026 |
| Nov 3, 2025 | Ruben Caballero director | DDisposition to issuer Common Stock | -8,295 | $0.00 | $0 | 535 | Nov 10, 2025 |
| Nov 3, 2025 | Jeremy Cogan CFO | DDisposition to issuer Common Stock | -31,871 | $0.00 | $0 | 5,204 | Nov 10, 2025 |
| Nov 3, 2025 | Shaheen Wirk director | DDisposition to issuer Common Stock | -6,841 | $0.00 | $0 | 0 | Nov 10, 2025 |
| Nov 3, 2025 | Brian Cullinan director | DDisposition to issuer Common Stock | -13,271 | $0.00 | $0 | 1,874 | Nov 10, 2025 |
| Nov 3, 2025 | Emily Fairbairn director | DDisposition to issuer Common Stock | -12,442 | $0.00 | $0 | 2,690 | Nov 10, 2025 |
| Nov 3, 2025 | Michael Aaron Leabman Chief Technology Officer | DDisposition to issuer Common Stock | -21,260 | $0.00 | $0 | 356 | Nov 10, 2025 |
| Nov 3, 2025 | John Mastrototaro Chief Executive Officer | DDisposition to issuer Common Stock | -39,226 | $0.00 | $0 | 1,944 | Nov 10, 2025 |
| Nov 3, 2025 | Emily Fairbairn director | AGrant or award Stock option (right to buy)derivative | +55,250 | $0.00 | $0 | 55,250 | Nov 10, 2025 |
| Nov 3, 2025 | Shaheen Wirk director | AGrant or award Stock option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Nov 10, 2025 |
| Nov 3, 2025 | John Mastrototaro Chief Executive Officer | AGrant or award Stock option (right to buy)derivative | +77,834 | $0.00 | $0 | 77,834 | Nov 10, 2025 |
| Nov 3, 2025 | Brian Cullinan director | AGrant or award Stock option (right to buy)derivative | +35,500 | $0.00 | $0 | 35,500 | Nov 10, 2025 |
| Nov 3, 2025 | Jeremy Cogan CFO | AGrant or award Stock option (right to buy)derivative | +84,834 | $0.00 | $0 | 84,834 | Nov 10, 2025 |
| Nov 3, 2025 | Ruben Caballero director | AGrant or award Stock option (right to buy)derivative | +21,500 | $0.00 | $0 | 21,500 | Nov 10, 2025 |
| Nov 3, 2025 | Michael Aaron Leabman Chief Technology Officer | AGrant or award Stock option (right to buy)derivative | +42,250 | $0.00 | $0 | 42,250 | Nov 10, 2025 |
| Oct 3, 2025 | Emily Fairbairn director | AGrant or award Common Stock | +31,028 | $0.00 | $0 | 151,315 | Oct 8, 2025 |
| Oct 3, 2025 | Ruben Caballero director | AGrant or award Common Stock | +20,685 | $0.00 | $0 | 88,294 | Oct 7, 2025 |
| Oct 3, 2025 | Jeremy Cogan CFO | AGrant or award Common Stock | +134,456 | $0.00 | $0 | 370,756 | Oct 7, 2025 |
| Oct 3, 2025 | Brian Cullinan director | AGrant or award Common Stock | +33,096 | $0.00 | $0 | 151,452 | Oct 7, 2025 |
| Oct 3, 2025 | John Mastrototaro Chief Executive Officer | AGrant or award Common Stock | +165,484 | $0.00 | $0 | 411,705 | Oct 7, 2025 |
| Oct 3, 2025 | Shaheen Wirk director | AGrant or award Common Stock | +20,685 | $0.00 | $0 | 68,412 | Oct 7, 2025 |
| Jul 3, 2025 | John Mastrototaro Chief Executive Officer | AGrant or award Common Stock | +149,257 | $0.00 | $0 | 246,221 | Jul 3, 2025 |
| Jul 3, 2025 | Shaheen Wirk director | AGrant or award Common Stock | +18,657 | $0.00 | $0 | 47,727 | Jul 3, 2025 |
| Jul 3, 2025 | Michael Aaron Leabman Chief Technology Officer | AGrant or award Common Stock | +139,925 | $0.00 | $0 | 216,163 | Jul 3, 2025 |
| Jul 3, 2025 | Brian Cullinan director | AGrant or award Common Stock | +29,851 | $0.00 | $0 | 118,356 | Jul 3, 2025 |
| Jul 3, 2025 | Jeremy Cogan CFO | AGrant or award Common Stock | +121,272 | $0.00 | $0 | 236,300 | Jul 3, 2025 |
| Jul 3, 2025 | Ruben Caballero director | AGrant or award Common Stock | +18,657 | $0.00 | $0 | 67,609 | Jul 3, 2025 |
| Jul 3, 2025 | Emily Fairbairn director | AGrant or award Common Stock | +27,985 | $0.00 | $0 | 120,287 | Jul 3, 2025 |
| May 9, 2025 | Michael Aaron Leabman Chief Technology Officer | AGrant or award Common Stock | +72,674 | $0.00 | $0 | 76,238 | May 13, 2025 |
| May 9, 2025 | Shaheen Wirk director | AGrant or award Common Stock | +29,070 | $0.00 | $0 | 29,070 | May 13, 2025 |
| May 9, 2025 | John Mastrototaro Chief Executive Officer | AGrant or award Common Stock | +77,521 | $0.00 | $0 | 96,964 | May 13, 2025 |
| May 9, 2025 | Emily Fairbairn director | AGrant or award Common Stock | +65,407 | $0.00 | $0 | 92,302 | May 13, 2025 |
| May 9, 2025 | Brian Cullinan director | AGrant or award Common Stock | +69,767 | $0.00 | $0 | 88,505 | May 13, 2025 |
| May 9, 2025 | Jeremy Cogan CFO | AGrant or award Common Stock | +62,986 | $0.00 | $0 | 115,028 | May 13, 2025 |
| May 9, 2025 | Ruben Caballero director | AGrant or award Common Stock | +43,605 | $0.00 | $0 | 48,952 | May 13, 2025 |
| Jan 2, 2025 | Ruben Caballero director | AGrant or award Stock Options (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jan 6, 2025 |
| Jan 2, 2025 | Brian Cullinan director | AGrant or award Stock Options (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jan 6, 2025 |
| Jan 2, 2025 | Emily Fairbairn director | AGrant or award Stock Options (Right to Buy)derivative | +10,333 | $0.00 | $0 | 10,333 | Jan 6, 2025 |
| Oct 9, 2024 | Ruben Caballero director | AGrant or award Stock option (right to buy)derivative10b5-1 | +130,000 | $0.00 | $0 | 130,000 | Oct 11, 2024 |
| Oct 9, 2024 | Brian Cullinan director | AGrant or award Stock option (right to buy)derivative10b5-1 | +130,000 | $0.00 | $0 | 130,000 | Oct 11, 2024 |
| Oct 9, 2024 | Emily Fairbairn director | AGrant or award Stock option (right to buy)derivative10b5-1 | +130,000 | $0.00 | $0 | 130,000 | Oct 11, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Ruben Caballerodirector
- Jeremy CoganCFO
- Brian Cullinandirector
- Emily Fairbairndirector
- Michael Aaron LeabmanChief Technology Officer
- John MastrototaroChief Executive Officer
- Shaheen Wirkdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.